Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy
dc.contributor.author | Bromberg, Mark B. | en_US |
dc.contributor.author | Feldman, Eva L. | en_US |
dc.contributor.author | Jaradeh, Safwan | en_US |
dc.contributor.author | Albers, James W. | en_US |
dc.date.accessioned | 2006-04-10T15:22:41Z | |
dc.date.available | 2006-04-10T15:22:41Z | |
dc.date.issued | 1992-01 | en_US |
dc.identifier.citation | Bromberg, Mark B., Feldman, Eva L., Jaradeh, Safwan, Albers, James W. (1992/01)."Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy." Journal of Clinical Epidemiology 45(1): 47-52. <http://hdl.handle.net/2027.42/30273> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T84-4BRKKSM-1R/2/daafb45c1c8dd6ec82adc32dcad66352 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/30273 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1738011&dopt=citation | en_US |
dc.description.abstract | Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) frequently includes use of immunosuppressive agents. Controlled treatment trials demonstrating efficacy are available only for prednisone and therapeutic plasma exchange (TPE). When these fail to achieve lasting clinical improvement after reduction or cessation of therapy, subsequent regimens are empiric, often leading to prolonged immunosuppression. It is not possible to predict who will respond to which agent and when. Administered individually, immunosuppressive agents may pose an acceptable risk, but cumulative effects of multiple agents in refractory patients may suppress the immune system and contribute to increased morbidity and mortality. Treatment difficulties with refractory CIDP patients have not been emphasized, and long-term effects of immunosuppression have focused on the risk of malignancy. In reviewing our clinical experience treating over 100 CIDP patients we identified approximately 20 patients who could be considered refractory to multiple immunosuppressive therapies and dependent upon long-term intermittent TPE. Two of these patients exemplify the morbidity associated with CIDP and its associated treatment. Our review of the clinical course of these patients raised issues about the use of multiple immunosuppressive agents, long-term goals, and long-term prognosis in CIDP. | en_US |
dc.format.extent | 584429 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical Center, Ann Arbor, MI 48109, U.S.A. | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical Center, Ann Arbor, MI 48109, U.S.A. | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical Center, Ann Arbor, MI 48109, U.S.A. | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical Center, Ann Arbor, MI 48109, U.S.A. | en_US |
dc.identifier.pmid | 1738011 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/30273/1/0000674.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0895-4356(92)90187-R | en_US |
dc.identifier.source | Journal of Clinical Epidemiology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.